Prime Medicine PRME Proceeds from research and development funding liability
Proceeds from research and development funding liability at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept prme:ProceedsFromResearchAndDevelopmentFundingLiability.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's proceeds from research and development funding liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's proceeds from research and development funding liability?
- Prime Medicine (PRME) reported proceeds from research and development funding liability of $0 in Q1 2026.
- How has Prime Medicine's proceeds from research and development funding liability changed year-over-year?
- Prime Medicine's proceeds from research and development funding liability decreased by 100.0% year-over-year, from $6M to $0.
- What does proceeds from research and development funding liability mean?
- This metric tracks cash inflows received from external parties specifically designated to fund research and development activities, often structured as a liability. It represents non-dilutive or debt-like financing that supports the advancement of the company's technology pipeline. It is a key indicator of the company's ability to secure external partnerships or grants to offset R&D costs.